Kyverna Therapeutics Statistics
Total Valuation
KYTX has a market cap or net worth of $503.69 million. The enterprise value is $295.83 million.
| Market Cap | 503.69M |
| Enterprise Value | 295.83M |
Important Dates
The next estimated earnings date is Tuesday, August 11, 2026, after market close.
| Earnings Date | Aug 11, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
KYTX has 60.80 million shares outstanding. The number of shares has increased by 12.42% in one year.
| Current Share Class | 60.80M |
| Shares Outstanding | 60.80M |
| Shares Change (YoY) | +12.42% |
| Shares Change (QoQ) | +28.16% |
| Owned by Insiders (%) | 1.84% |
| Owned by Institutions (%) | 39.36% |
| Float | 35.55M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | 997.04 |
| PB Ratio | 2.54 |
| P/TBV Ratio | 2.55 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 8.15, with a Debt / Equity ratio of 0.17.
| Current Ratio | 8.15 |
| Quick Ratio | 7.97 |
| Debt / Equity | 0.17 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -144.82 |
Financial Efficiency
Return on equity (ROE) is -74.55% and return on invested capital (ROIC) is -44.48%.
| Return on Equity (ROE) | -74.55% |
| Return on Assets (ROA) | -39.55% |
| Return on Invested Capital (ROIC) | -44.48% |
| Return on Capital Employed (ROCE) | -72.04% |
| Weighted Average Cost of Capital (WACC) | 14.23% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.21M |
| Employee Count | 129 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +157.05% in the last 52 weeks. The beta is 1.96, so KYTX's price volatility has been higher than the market average.
| Beta (5Y) | 1.96 |
| 52-Week Price Change | +157.05% |
| 50-Day Moving Average | 8.83 |
| 200-Day Moving Average | 7.95 |
| Relative Strength Index (RSI) | 47.62 |
| Average Volume (20 Days) | 810,870 |
Short Selling Information
The latest short interest is 5.74 million, so 9.44% of the outstanding shares have been sold short.
| Short Interest | 5.74M |
| Short Previous Month | 5.28M |
| Short % of Shares Out | 9.44% |
| Short % of Float | 16.15% |
| Short Ratio (days to cover) | 6.71 |
Income Statement
| Revenue | n/a |
| Gross Profit | -126.36M |
| Operating Income | -163.79M |
| Pretax Income | -156.40M |
| Net Income | -156.40M |
| EBITDA | -162.14M |
| EBIT | -163.79M |
| Earnings Per Share (EPS) | -$3.22 |
Balance Sheet
The company has $236.45 million in cash and $33.76 million in debt, with a net cash position of $202.69 million or $3.33 per share.
| Cash & Cash Equivalents | 236.45M |
| Total Debt | 33.76M |
| Net Cash | 202.69M |
| Net Cash Per Share | $3.33 |
| Equity (Book Value) | 195.58M |
| Book Value Per Share | 3.23 |
| Working Capital | 212.05M |
Cash Flow
In the last 12 months, operating cash flow was -$150.39 million and capital expenditures -$5,000, giving a free cash flow of -$150.40 million.
| Operating Cash Flow | -150.39M |
| Capital Expenditures | -5,000 |
| Depreciation & Amortization | 1.65M |
| Net Borrowing | 24.15M |
| Free Cash Flow | -150.40M |
| FCF Per Share | -$2.47 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
KYTX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -12.42% |
| Shareholder Yield | n/a |
| Earnings Yield | -31.37% |
| FCF Yield | -30.17% |
Analyst Forecast
The average price target for KYTX is $30.40, which is 266.93% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $30.40 |
| Price Target Difference | 266.93% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 6 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |